The Jenex Corporation
The Jenex Corporation
- ISIN: CA4760231064
- Land: .
Nachricht vom 18.04.2017 | 15:17
Jenex to Test TherOZap(TM) Working Prototype and Topical Cannabidiol Oil Against the Zika and West Nile Viruses
DGAP-News: The Jenex Corporation / Key word(s): Miscellaneous
Toronto, Ontario--(Newsfile Corp. - April 18, 2017) - The Jenex Corporation (TSXV: JEN.H) ('Jenex' or the 'Company'), a progressive medical device technology company, would like to report the testing of a topical cannabidiol ('CBD') oil from hemp with Jenex's platform technology, including Jenex's TherOZap™ device. The topical cannabidiol oil will be included in the lab tests, to be conducted through University Health Network and coordinated through Techna Institute at UHN located in Toronto, Ontario, to determine the effectiveness at inactivating both the Zika and West Nile viruses as previously announced on April 7th, 2017.
There is a growing body of clinical research demonstrating CBD's potential therapeutic uses against viruses. The clinical research is revealing and is demonstrating that CBD can have positive health effects as CBD increases nitric oxide levels in the human body which may prove to be an effective treatment to combat viral infections such as the Zika and West Nile viruses. There are high levels of CBD in hemp but almost no tetrahydrocannabinol (THC), the psychoactive component that is prevalent in cannabis.
Jenex will work with partners in the medical marijuana industry to license a topical CBD oil or working through formulators Jenex will create its own topical CBD oil to be used with the TherOZap™ device. Several natural health products in topical formulations with unique delivery systems could be developed.
Rob Fia, CEO commented:
'We are excited to test our platform technology, including our TherOZap™ device, with a topical cannabidiol oil. Our platform technology combined with a unique CBD topical delivery system may prove beneficial in potentially combating the increasingly troublesome Zika virus problem now affecting many parts of the world.'
RISKS AND UNCERTAINTIES INHERENT TO THE MEDICAL MARIJUANA BUSINESS
The Company plans to continue its principal business of developing its consumer product platform technology. The Company's pursuit of the use of hemp oil with CBD is supplementary to the consumer product platform technology business it is currently engaged in. The board of directors have approved the Company's testing of hemp oil with CBD and to the Company's knowledge, this is the only approval required for the Company's pursuit of opportunities to test hemp oil with CBD with its platform technology. There are risks and uncertainties inherent to the medical marijuana businesses and it should be noted that the Company does not intend to acquire a medical marijuana license.
Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997.
Jenex continues to further develop, and explore other applications, for its platform technology. If you would like to stay informed on the development of TherOZap™ please visit www.therozap.com.
Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX (NEX: JEN.H). For more information visit: www.thejenexcorporation.com or www.therozap.com.
About Techna Institute:
Techna is an institute of the University Health Network, in collaboration with the University of Toronto, focused on the accelerated development and exploitation of technology for improved health. Techna is designed to shorten the time interval from technology discovery and development to application for the benefit of patients and the health care system. It also stimulates and facilitates the innovation cycle through a continuum of clinically driven innovation, technology & process development, and translational research. For more information visit: technainstitute.com.
About University Health Network:
University Health Network (UHN) is a major landmark in Canada's healthcare system and a teaching partner of the University of Toronto. UHN consists of Toronto General and Toronto Western Hospitals, the Princess Margaret Cancer Centre, Toronto Rehabilitation Institute and the Michener Institute for Education at UHN. The scope of research and complexity of cases at University Health Network has made it a national and international source for discovery, education and patient care. It has the largest hospital-based research program in Canada, with major research in cardiology, transplantation, neurosciences, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. For more information visit: www.uhn.ca.
FORWARD LOOKING STATEMENTS
Certain statements in this news release constitute 'forward-looking' statements. These statements relate to future events or the Company's future performance and include tests involving the Company's TherOZap™ technology and CBD oil from hemp as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. In addition to other risks, the Company's tests involving TherOZap™ and CBD oil from hemp may prove to be unsuccessful against the Zika or West Nile viruses and the Company may be unable to complete the consumer product TherOZap™ technology. Further, the Company may not complete the tests on the schedule it expects as described in this news release or attract capital for marketing to ramp up sales or establish recurring revenue in the future to generate cash flow for the Company. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
For further information please contact:
The Jenex Corporation
NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES
Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/26208
|Company:||The Jenex Corporation|
|End of News||DGAP News Service|
GBC im Fokus
23. MKK – Münchner Kapitalmarkt Konferenz
Für: Institutionelle Investoren & Presse
Wann: 26. & 27. April 2017, 9 - 17 Uhr
Wo: The Charles Hotel - Rocco Forte Hotels, München
GBC im Fokus
Neovacs S.A.: Kursziel auf 3,30 € angehoben
In den letzten Monaten hatte die Neovacs S.A. einen positiven Newsflow. Im Vordergrund steht die Vertriebspartnerschaft für den chinesischen Markt, wodurch sich bis nach dem ersten Vermarktungsjahr Gesamterträge von bis zu 65 Mio. € ergeben können. Zudem verläuft der klinische Zulassungsprozess des IFNα-Kinoid zur Behandlung von SLE (Systemischer Lupus) und Dermatomyositis planmäßig. Wir haben in unsere Bewertung aktualisiert und ein Kursziel von 3,30 € je Aktie (bisher: 2,90 €) ermittelt. Das Rating lautet weiter KAUFEN.
Der AKTIONÄR News
24. April 15:21 Schröders Nebenwerte-Watchlist: Adesso, Koenig & Bauer, SLM ...
24. April 11:41 Mologen: Biotech-Aktie mit Kurssprung nach Studiendaten
24. April 11:37 Commerzbank: Zweistellige Kurse? Na klar!
24. April 11:34 Egbert Prior: Diese Aktie ist auf der Überholspur
Q1 Results 2017
10. Mai 2017
Original-Research: JDC Group AG (von GBC AG): Kaufen
24. April 2017